



**Annual Liver Cancer Virtual CME Conference**  
**October 29, 2022**  
**9:45 a.m. – 3:00 p.m. EST**

At course completion, attendees should be able to: Increase Knowledge Understand the molecular classification of HCC Understand the multidisciplinary approach to management of HCC Competency Define the mechanisms that lead to the development of hepatocellular cancer (HCC) Performance Discuss the available evidence-based data on promising treatment options for advanced HCC Discuss the advances in research and development

**Program Overview**

The goal of this course module is to help clinicians and other service providers understand the management of Hepatocellular Carcinoma in the US population, innovations in therapies and advances in research and development.

**Learning Objectives**

At course completion, attendees should be able to:

**Increase Knowledge**

Understand the molecular classification of HCC

Understand the multidisciplinary approach to management of HCC

**Competency**

Define the mechanisms that lead to the development of hepatocellular cancer (HCC)

**Performance**

Discuss the available evidence-based data on promising treatment options for advanced HCC

Discuss the advances in research and development

**Course Directors**

Dulabh K. Monga, MD

Program Director

Hematology Oncology Fellowship

Assistant Professor of Medicine

Temple University School of Medicine

Allegheny Health Network

Pittsburgh, PA

Satdarshan (Paul) Singh Monga, MD

UPMC Endowed Chair for Experimental Pathology

Professor of Pathology and Medicine

Director, Pittsburgh Liver Research Center,

Chief and Vice Chair, Division of Experimental Pathology

University of Pittsburgh, School of Medicine and UPMC

Pittsburgh, PA

## **Schedule**

### **9:45 -10:00 a.m. Welcome and Overview**

Dulabh K Monga, MD and Satdarshan (Paul) Monga, MD  
Course Directors

Suzanna Masartis  
CEO, Community Liver Alliance

### **10:00 a.m. How Does Liver Cancer Develop?**

Satdarshan (Paul) Monga, MD  
Professor and Vice Chair of Pathology  
Director, Pittsburgh Liver Research Center  
University of Pittsburgh and UPMC  
Pittsburgh, PA

### **10:30 a.m. HCC Surveillance in High Risk Liver Cancer**

Renumathy Dhanasekaran, MD  
Assistant Professor, Division of Gastroenterology and Hepatology  
Stanford University School of Medicine  
Stanford, CA

### **11:00 a.m. Role of Surgical Resection and Transplantation in HCC Management**

Rachel Tindall, MD, FACS  
Transplant Surgeon, Hepatobiliary & Pancreas Cancer  
Allegheny Health Network  
Pittsburgh, PA

### **11:30 a.m. Concurrent Session**

#### **Role of Locoregional Therapies in HCC Management**

Riad Salem, MD  
Vice-Chair, Image-Guided Therapy  
Chief, Interventional Radiology and Oncology  
Department of Radiology  
Feinberg School of Medicine  
Northwestern University  
Chicago, IL

### **12:00 p.m. BREAK/Exhibits**

### **12:30 p.m. Medical Management of HCC**

Dulabh K Monga, MD  
Associate Professor of Medicine  
Drexel University School of Medicine  
Allegheny Health Network Cancer Institute  
Pittsburgh, PA

**1:00 p.m. Radiation Therapy for HCC**

Paul Renz, DO  
Radiation Oncology Specialist  
Allegheny Health Network Cancer Institute  
Pittsburgh, PA

**1:30 p.m. Molecular Pathology of Hepatobiliary Tumors**

Aatur Singhi, MD, PhD  
Assistant Professor of Pathology  
University of Pittsburgh and UPMC  
Pittsburgh, PA

**2:00 p.m. Advances in the Management of Biliary Tract Cancers**

Rachna Shroff, MD, MS  
Associate Professor of Medicine  
Chief, GI Medical Oncology  
University of Arizona Cancer Center  
Tucson, AZ

**2:30 p.m. Palliative Care of Cancer Patients**

Sidra Anwar, MD  
Hospice & Palliative Medicine Specialist  
Allegheny Health Network  
Pittsburgh, PA

**3:00 p.m. Case Presentations/Q & A**

**Resectable/Transplantable HCC**  
**Non-Resectable Non-Transplantable HCC and**  
**Medical and Locoregional Options**  
**Intrahepatic Cholangiocarcinoma**

Paul Renz, DO  
Dulabh Monga, MD  
Riad Salem, MD  
Rachna Shroff, MD  
Rachel Tindall, MD

**4:00 Adjournment****Accreditation and credit designation**

In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and Community Liver Alliance. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physician (CME)**

The University of Pittsburgh designates this live activity for a maximum of 5.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

**Faculty Disclosure**

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The information presented at this program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.